{"slug":"semax","seoKey":"semax","displayName":"Semax","codes":["ACTH(4-7)PGP","MEHFPGP"],"synonyms":["Met-Glu-His-Phe-Pro-Gly-Pro","ACTH (4-10) analogue","ACTH (4-7), Pro-Gly-Pro-","L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-prolylglycyl-L-proline","registered as a prescription medicine in the Russian Federation since 1994 (an eighth market the registry does not track)"],"legalClass":"rx","identifiers":{"cas":"80714-61-0","pubchemCid":9811102,"unii":"I5FAL2585H","inchikey":"AFEHBIGDWIGTEH-AQRCPPRCSA-N","wikidataQid":"Q4415058","formula":"C37H51N9O10S","molecularWeight":813.9,"sequence":"MEHFPGP"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved and not a component of an approved medicinal product. The regulator states there is no pharmacopoeial monograph for the free base or the acetate; three openFDA endpoints returned no match on 2026-09-06.","source":"https://www.fda.gov/media/193342/download"},{"market":"EU","status":"not_approved","note":"No authorised medicinal product, no centralised procedure and no monograph in the European Pharmacopoeia. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=semax"},{"market":"DE","status":"not_approved","note":"No national or EU marketing authorisation; a substance with a medicinal purpose may not be placed on the market without one. The Russian authorisation has no legal effect in Germany. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=semax"},{"market":"UK","status":"not_approved","note":"No marketing authorisation and no substance-specific rule found. No entry found on 2026-09-06.","source":"https://products.mhra.gov.uk/search/?search=semax"},{"market":"AU","status":"not_approved","note":"Not registered and not named in the Poisons Standard; the full text was searched on 2026-09-06 without a hit. Absence of a listing does not make an unregistered medicine freely available.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no drug identification number; brand name and active ingredient queries both returned empty results on 2026-09-06.","source":"https://health-products.canada.ca/dpd-bdpp/"},{"market":"CH","status":"not_approved","note":"No marketing authorisation. No entry found in the list of authorised human medicinal products on 2026-09-06.","source":"https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html"}],"devStage":"approved","strongestEvidence":"observational","wada":{"status":"unclear","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://www.wikidata.org/wiki/Q4415058","https://pubchem.ncbi.nlm.nih.gov/compound/9811102"],"lastVerified":"2026-09-06","version":"1.0","published":true,"locale":"en","title":"Semax: what the studies show, status and safety","summary":"Semax is a laboratory-made chain of seven amino acids, copied from a fragment of the stress hormone ACTH but without its hormone action. It is a licensed prescription medicine in exactly one country, Russia, where it has been sold as nasal drops since 1994. Nowhere else is it approved. Not a single study of it appears in the international trials register. No safety testing of the kind regulators normally require has ever been published. In May 2026 the US Food and Drug Administration reviewed it and its own scientists advised against letting pharmacies mix it into medicines made up to order.","updated":"2026-09-06","url":"https://mypep.app/peptides/semax"}